Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid MalignanciesDavid Olmos(Queen's University Belfast), Sarah P. Blagden(Queen's University Belfast)Clinical Cancer ResearchApril 2, 201110.1158/1078-0432.ccr-10-2946Cited by 168SaveCiteExport RISWatch citationsRelated PapersFirst-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer|Clinical Cancer Research|2014|47